53312-82-6

Basic information

• Product Name: 4-amino-2-bromobenzonitrile
• Synonyms: 4-amino-2-bromobenzonitrile;Bromo-4-amino-benzonitrile
• CAS NO: 53312-82-6
• Molecular Formula: C₇H₅BrN₂
• Molecular Weight: 197
• Mol File: 53312-82-6.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 355.5±32.0 °C(Predicted)
• Appearance: Yellow/Powder
• Density: 1.68
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 0.65±0.10(Predicted)
• CAS DataBase Reference: 4-amino-2-bromobenzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-amino-2-bromobenzonitrile(53312-82-6)
• EPA Substance Registry System: 4-amino-2-bromobenzonitrile(53312-82-6)

Safety Data

• Safety Statements: 24/25
• TSCA: y
• HazardClass: 6.1
• Hazardous Substances Data: 53312-82-6(Hazardous Substances Data)

Upstream product

• 36282-26-5 2-bromo-4-fluorobenzonitrile 
• 34662-35-6 2-bromo-4-nitrobenzonitrile 
• 13296-94-1 2-bromo-4-nitroaniline 
• 100-01-6 4-nitro-aniline 

Downstream Products

• 1008714-30-4 [1-(3-bromo-4-cyanophenyl)-2-oxo-2,4,5,6,7,7a-hexahydro-1H-indol-3-yl]-acetic acid 
• 1201684-65-2 3-bromo-4-cyano-benzenesulfonyl chloride 
• 1220099-40-0 C₇H₄BrIN₂ 
• 1189353-62-5 2-bromo-4-(dimethylamino)benzonitrile 
• 1425822-14-5 N-(3-bromo-4-cyanophenyl)imidodicarbonic acid bis(1,1-dimethylethyl) ester 
• 1425822-16-7 (S)-methyl 2-(5-(bis(tert-butoxycarbonyl)amino)-2-cyanophenylamino)-4-methylpentanoate 
• 1425822-28-1 C₂₄H₃₃N₃O 
• 1425822-30-5 C₂₇H₃₇N₃O₃ 
• 1425822-32-7 C₂₅H₃₃N₃O₃ 
• 1425822-37-2 (S)-ethyl 4-[8-amino-1,2,4,5-tetrahydro-2-(2-methylpropyl)-4-(3-methylbutyl)-3-oxo-3H-1,4-benzodiazepin-7-yl]-3-[2-(benzyloxy)ethoxy]benzoate 
• 1425822-40-7 C₂₉H₄₁N₃O₅ 
• 1459140-41-0 1-(3-bromo-4-cyanophenyl)-3-(5-(pyridin-4-yl)-1,3,4-thiadiazol-2-yl)urea 
• 1261494-69-2 C₈H₃BrN₂O 

Relevant articles and documents

Structure-activity relationship of benzodiazepine derivatives as LXXLL peptide mimetics that inhibit the interaction of vitamin D receptor with coactivators

Suppression of vitamin D receptor (VDR)-mediated transcription is expected to be of therapeutic value in Paget's disease of bone. It is known that interaction between VDR and coactivators is necessary for VDR transactivation, and the interaction occurs wh

FUSED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION

Disclosed are fused heterocyclic compounds of Formula (I) or pharmaceutically-acceptable salts or stereoisomers thereof. Also disclosed are methods of using such compounds in the treatment of at least one androgen receptor-associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.